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	Take home message: 
Persistent airway eosinophilia/Th2 inflammation in severe asthma is associated with reduced 
epithelial SOCS1 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	ABSTRACT 
Severe asthma represents a major unmet clinical need. Eosinophilic inflammation persists in 
the airways of many patients with uncontrolled asthma, despite high dose inhaled 
corticosteroid therapy. Suppressors of cytokine signalling (SOCS) are a family of molecules 
involved in the regulation of cytokine signalling via inhibition of the JAK-STAT pathway. 
We examined SOCS expression in the airways of asthma patients and investigated whether 
this is associated with persistent eosinophilia. 
Healthy controls, mild/moderate asthmatics and severe asthmatics were studied. Whole 
genome expression profiling, qPCR and immunohistochemical analysis were used to examine 
expression of SOCS1, SOCS2 and SOCS3 in bronchial biopsies. Bronchial epithelial cells 
were utilised to examine the role of SOCS1 in regulating IL-13 signalling in vitro. 
SOCS1 gene expression was significantly lower in the airways of severe asthmatics 
compared to mild/moderate asthmatics, and was inversely associated with airway 
eosinophilia and other measures of Th2 inflammation. Immunohistochemistry demonstrated 
SOCS1 was predominantly localised to the bronchial epithelium. SOCS1 overexpression 
inhibited IL-13-mediated CCL26 (eotaxin-3) mRNA expression in bronchial epithelial cells. 
Severe asthma patients with persistent airway eosinophilia and Th2 inflammation have 
reduced airway epithelial SOCS1 expression. SOCS1 inhibits epithelial IL-13 signalling, 
supporting its key role in regulating Th2 driven eosinophilia in severe asthma.  
 
 
 
 
 
 
	INTRODUCTION 
Asthma is one of the most common chronic conditions affecting approximately 300 million 
people worldwide.[1] Most patients with asthma achieve adequate disease control with 
bronchodilator and inhaled corticosteroid therapy.[2] However, approximately 10% of 
patients suffer from severe uncontrolled asthma despite the use of high dose inhaled 
corticosteroids, and in many cases systemic corticosteroids. This cohort of asthma patients 
represent a significant unmet clinical need.[3] 
Asthma is a heterogeneous disorder thus current research is endeavouring to identify and 
characterise distinct phenotypes, particularly in severe disease.[4, 5] Both clinical and 
molecular phenotyping have been utilised to describe populations of asthma patients in terms 
of inflammatory biology.[6-8] 
A key feature in many patients with severe asthma is persistent eosinophilic airway 
inflammation despite high dose corticosteroid treatment.[9, 10] The major group of cytokines 
implicated in driving this inflammation are the Th2-associated cytokines, namely IL-4, IL-5 
and IL-13. IL-13 is a key cytokine contributing to the pathophysiological features of asthma 
including airway hyper-responsiveness, mucus hypersecretion and airway remodelling and 
IL-13 overexpression persists in a subgroup of patients with severe asthma despite high dose 
steroid treatment.[10, 11] 
Th2 cytokines mediate their actions via the JAK-STAT pathway and cytokine signalling is 
tightly regulated by several molecules including the suppressors of cytokine signalling 
(SOCS). SOCS are a family of 8 proteins, comprising SOCS1-7 and CIS, which inhibit 
cytokine signalling through inhibition of the JAK–STAT pathway in a negative feedback 
manner.[12] SOCS1 was the first of the SOCS family to be discovered.[13] In vitro cell 
cultures and in vivo animal models have demonstrated that SOCS1 is a negative regulator of 
	Th2-dependent pathways, achieved by inhibition of the phosphorylation of STAT6.[14, 15] 
SOCS2 inhibits growth hormone and insulin-like growth factor [16] and has been shown to 
regulate the expression of other SOCS molecules.[17] Recently, we have shown that SOCS2 
knockout mice have an increased susceptibility to Th2 mediated airway inflammation 
compared to wild type mice, due to elevated SOCS3 levels.[18] SOCS3 mRNA expression is 
reported to be increased in the peripheral T cells of asthma patients [19, 20] and constitutive 
SOCS3 expression in the T cells of mice resulted in exaggerated lung inflammation in a 
mouse model of asthma.[20] 
The principal aim of this study was to examine SOCS1, SOCS2 and SOCS3 expression in the 
airways of healthy controls, mild/moderate asthmatics and severe asthmatics and to explore 
the relationship between SOCS expression and persistent eosinophilic inflammation within 
the airway. 
 
 
 
 
 
 
 
 
 
 
 
 
	METHODS 
Patient cohort 
Data from this well characterised cohort of subjects has been published 
previously.[10, 21, 22] Healthy controls (n=17), mild/moderate asthmatics (n=29) and severe 
asthmatics (n=18) were recruited from two UK specialist asthma centres, Belfast City 
Hospital and Glenfield Hospital, Leicester (demographic characteristics shown in Table 1). 
Clinical assessment protocols ensured patients had severe asthma as defined by current 
ERS/ATS guidelines.[23] Further details of asthma patients in the study, including asthma 
treatment, can be found in the online supplementary file (Table E1). This study was approved 
by Research Ethics Committees of both institutions and written informed consent obtained 
from all subjects (see online supplementary file). 
 
Table 1. Demographic characteristics of study participants. 
 
 
Healthy Controls 
(n=17) 
Mild-Moderate 
Asthmatics (n=29) 
Severe 
Asthmatics (n=18) 
 
P value 
Age (years) 31.82 ± 11.74 31.86 ± 9.93 46.94 ± 10.70 <0.0001 
Sex, male/female (n) 7 / 10 17 / 12 12 / 6 ns 
Duration of asthma (years) N/A 14.59 ± 13.76 19.39 ± 15.01 ns 
Asthma onset (age) N/A 17.28 ± 13.29 27.56 ± 18.99 0.03 
FEV1 (L/min) 3.69 ± 0.62 3.48 ± 0.73 2.45 ± 0.60 <0.0001 
FEV1 (% predicted) 102 ± 12.01 92.44± 16.78 75.17 ± 16.79 <0.0001 
FEV/FVC (%) 82.11 ± 11.57 73.43 ± 11.01 61.3 ± 13.48 0.0017 
Mean asthma exacerbations/year N/A 2.2 ± 0.83 5.26 ± 4.14 <0.0001 
Regular inhaled steroid n (%) N/A 20 (69) 18 (100) ns 
BDP equivalent (µg) N/A 400 (0 - 800) 1600 (800 - 1700) <0.0001 
Systemic steroids n (%) N/A 0 (0) 12 (67) <0.0001 
Prior smoking n (%) 1 (6) 6 (21) 7 (39) ns 
	Beclomethasone Dipropionate (BDP) equivalent is expressed as median ± IQR. Age, duration 
of asthma, asthma onset, FEV1 (L/min), FEV1 (% predicted), FEV1/FVC (%), mean asthma 
exacerbations/year are expressed as mean ± standard deviation. Between group comparisons 
were calculated using ANOVA with Bonferroni’s multiple comparisons test or Kruskal 
Wallis with Dunn’s multiple comparison test where appropriate, t-test when only asthma 
groups compared or Chi-squared for categorical variables; ns = not significant.  
 
Bronchoscopy 
Each participant underwent bronchoscopy and biopsy specimens were taken from the right 
middle lobe and lower lobe carinae. Biopsies were immediately placed in RNA preservative 
(Ambion, USA) or fixed overnight before embedding in glycol methacrylate (GMA) as 
described previously.[24]  
 
Gene expression analyses 
Bronchial biopsies were homogenised, RNA extracted and amplified for Agilent two colour 
Whole Human Genome 4x44k gene expression microarray analysis as previously 
described.[25] Th2 score was calculated as described previously and details can be found in 
the online supplementary file.[8, 10, 25] TaqMan® Gene Expression Assays (Applied 
Biosystems, USA) were used as per manufacturer’s instructions. GAPDH was utilised as the 
house keeping gene. qPCR values were calculated using the ΔΔCt method with relative gene 
expression calculated as -ΔΔCt.[26] Further details are available in the online supplementary 
file. 
 
 
 
	Immunohistochemistry (IHC) 
Sections of bronchial biopsies were cut at 2µm, immunostained as described previously [24] 
and counterstained with Mayer’s haematoxylin. Negative controls, using an isotype and/or 
omitting primary antibody, were employed. The lamina propria was measured in biopsy 
sections using a computer analysis system (LAS V3.7 software, Leica, Germany). For 
enumerating cellular inflammatory infiltrate, individual positively stained nucleated cells 
were counted and expressed per mm2 of tissue. Figure E1 in the online supplementary file 
shows exemplar micrographs of inflammatory cell staining. IHC was additionally employed 
to determine localisation of SOCS proteins in patient biopsies. Full details of antibodies are 
available in the online supplementary file.  
 
Bronchial epithelial cell cultures 
The BEAS-2B cell line (ATCC, USA) was cultured in Dulbecco's Modified Eagle Medium 
supplemented with 5% foetal calf serum and 1% Penicillin/Streptomycin. Primary bronchial 
epithelial cells (PBECs) were obtained from healthy volunteers. This work was approved by 
Research Ethics Committee as detailed in the online supplementary file and written informed 
consent was gained from all subjects.[22] PBECs were cultured in airway epithelial cell basal 
medium containing a supplement pack (Promocell, Germany). Human recombinant IL-13 
(R&D Systems, USA) was used at 50 ng/ml. In vitro experiments were carried out a 
minimum of 3 times. 
 
Transfections 
Myc-tagged full-length SOCS1 in a pcDNA3 plasmid, along with the empty vector, were a 
generous gift from Prof. A. Yoshimura (Keio University School of Medicine, Japan). BEAS-
2B cells were plated in antibiotic-free media and transfected using Lipofectamine 2000 
	(Invitrogen, UK). PBECs were transfected by electroporation using the NEON transfection 
system (Life Technologies, UK). Media was changed 6 hours post-transfection and cell 
stimulations were carried out 24 hours post-transfection.  
 
Western blotting 
Cells were lysed and 30 µg of protein was immunoblotted with antibodies against SOCS1, 
SOCS2, SOCS3, c-Myc and γ-tubulin as described in the online supplementary file.  
 
Statistical analyses 
GraphPad, Prism 5 software was used to analyse data. Data is presented as median (IQR) 
where appropriate. Kruskal-Wallis test, Mann–Whitney U test, Student t-test and Spearman’s 
Rank correlations were used for statistical tests unless otherwise stated. PBEC data was 
transformed (log10) prior to statistical analysis. 
 
 
RESULTS 
Increased Th2 inflammatory measures in study participants with asthma.  
Peripheral blood eosinophil numbers and blood IgE levels were significantly elevated in 
mild/moderate asthmatics and severe asthmatics as compared to healthy controls (Figure 1A 
and 1B respectively). Quantification of eosinophils using IHC showed a trend of increasing 
numbers of eosinophils in the lamina propria of bronchial biopsies with increasing asthma 
severity (healthy control, mild/moderate asthma and severe asthma group median values were 
4.59, 9.70 and 12.93 respectively, p=0.07) (Figure 1C). There were no significant differences 
noted in the number of neutrophils or mast cells between the study groups (Table E2 in the 
online supplementary file). The previously generated gene expression microarray Th2 
	signature from asthma patients is a composite measure of IL-13 induced epithelial genes.[8, 
10, 25] There was also a trend for increasing Th2 biopsy signature values with increasing 
asthma severity (p=0.057). There was a significant positive correlation between the intensity 
of the Th2 biopsy signature and the number of eosinophils/mm2 of lamina propria of the 
asthma patients (Figure 1E). No correlation was observed between neutrophils or mast cells 
and the Th2 signature (Figure E2 in the online supplementary file).  
 
Decreased SOCS1 mRNA expression in bronchial biopsies from severe asthmatics 
compared to mild/moderate asthmatics.  
Gene expression of SOCS1, SOCS2 and SOCS3 mRNA in bronchial biopsies of healthy 
controls, mild/moderate asthmatics and severe asthmatics was assessed using qPCR. SOCS1 
expression was significantly decreased in the bronchial biopsies of severe asthmatics 
compared to mild/moderate asthmatics (Figure 2A). However, there were no differences 
observed in SOCS2 and SOCS3 gene expression levels between groups (Figure 2B and 2C 
respectively). Of note SOCS1 mRNA was decreased in the airways of asthma patients 
receiving high dose inhaled corticosteroids compared those receiving low dose inhaled 
corticosteroids but there was no difference in SOCS2 or SOCS3 expression (Figure E3). 
 
SOCS1 gene expression is decreased in patients with persistent Th2 inflammation and 
eosinophilia in the airways. 
Significant negative correlations were observed between SOCS1 gene expression and both 
the Th2 biopsy signature and eosinophil numbers in the lamina propria of bronchial tissue in 
asthma patients (Figure 3A and 3B respectively). There were no significant correlations 
identified between SOCS2 or SOCS3 and Th2 biopsy signature or eosinophil numbers in 
bronchial biopsies (Figure E4 in the online supplementary file). To further examine the 
	relationship between SOCS1 expression and tissue eosinophilia, subjects were dichotomised 
by the number of eosinophils in the lamina propria of their bronchial biopsies (eosinophil 
counts were dichotomised around the median value for eosinophils/mm2 within the lamina 
propria). Participants with high eosinophils (≥9.2 eosinophils/mm2 within the lamina propria) 
were found to have significantly decreased levels of SOCS1 when compared to those 
presenting with low eosinophils (<9.2 eosinophils/mm2 within the lamina propria) (Figure 
3C). Subjects dichotomised into eosinophil high and eosinophil low subsets again showed no 
difference in SOCS2 or SOCS3 expression between the two groups (Figure E5 in the online 
supplementary file). As CCL26 is highly induced in response to type 2 inflammation the 
relationship between this chemokine and SOCS1 was explored. As anticipated a negative 
correlation was observed indicating patients with low SOCS1 expression fail to inhibit the 
Th2 induced CCL26 (Figure 3D).	
 
Localisation of SOCS proteins in bronchial biopsies.  
To examine the cellular localisation of SOCS protein expression, IHC was employed to stain 
for SOCS1, SOCS2 and SOCS3 in the bronchial biopsies. SOCS1 was localised 
predominantly to the bronchial epithelium and observed in the differentiated pseudo-
columnar cells rather than the basal cells (Figure 4 shows representative images of A, 
negative control staining, and SOCS1 staining of B, healthy controls, C, mild/moderate 
asthmatics and D, severe asthmatics). There was minimal SOCS2 staining evident throughout 
the bronchial biopsies with only a small number of infiltrating inflammatory cells in the 
lamina propria staining positive for SOCS2 (Figure E6 in the online supplementary file). 
SOCS3 was found to be present both in the epithelium and in large, 
mononuclear/macrophage like cells in the lamina propria (Figure E6 in the online 
supplementary file).  
	Inhibition of IL-13 induced CCL26 mRNA in bronchial epithelial cell SOCS1 
overexpression models.  
Due to the localisation of SOCS1 to the bronchial epithelium and its potential role in 
inhibiting Th2 inflammation within the severe asthmatic airway, the BEAS-2B cell line was 
initially used to further characterise the role of SOCS1 in IL-13 signalling in the bronchial 
epithelium. We examined induction of SOCS1 mRNA in BEAS-2B cells after IL-13 
(50 ng/ml) exposure and found it was rapidly up-regulated within 2 hours of stimulation and 
remained elevated over the 24 hour time course. SOCS2 and SOCS3 mRNA were not 
induced in response to IL-13 treatment (Figure 5A). We then investigated the expression of 
SOCS1, SOCS2 and SOCS3 protein in response to IL-13 stimulation observing SOCS1 but 
not SOCS2 or SOCS3 induction (Figure 5B). CCL26 (eotaxin-3) mRNA is upregulated in 
vitro by IL-13 stimulation and in bronchial biopsies of asthma patients with high levels of 
Th2 inflammation in their airways.[25] CCL26 mRNA upregulation was confirmed in 
BEAS2-B cultures stimulated with IL-13 (Figure 5C). To investigate the role of SOCS1 in 
the regulation of IL-13 induced CCL26, SOCS1 was overexpressed in BEAS-2B cells using a 
Myc-tagged SOCS1 plasmid. Transfection with the SOCS1 plasmid lead to overexpression of 
SOCS1 in the cells compared to the empty vector control (Figure 5D). Next, cells were 
transfected with either the empty vector or the Myc-tagged SOCS1 plasmid for 24 hours, then 
stimulated with IL-13 for a further 24 hours. A significant decrease in CCL26 mRNA was 
observed in the SOCS1 overexpressing cells (Figure 5D).  
We then wished to confirm these observations in primary bronchial epithelial cells (PBECs). 
PBECs were stimulated with IL-13 (50 ng/ml) over a 24 hour time course. SOCS1 mRNA 
was again rapidly up-regulated 2 hours after stimulation and remained elevated over the 24 
hour time course and SOCS2 and SOCS3 mRNA were not induced (Figure 6A). As 
anticipated, CCL26 mRNA was also induced in IL-13-stimulated cells (Figure 6B). PBECs 
	were transfected using electroporation (transfection efficiencies were routinely greater than 
55% as shown in Figure E7) and again, overexpression of SOCS1 reduced IL-13 induction of 
CCL26 mRNA compared to empty vector control (Figure 6C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	DISCUSSION 
Severe asthma affects up to 10% of all asthma patients, but the underlying mechanisms 
causing persistent eosinophilic inflammation, despite high dose inhaled corticosteroid 
treatment, are yet to be fully elucidated.[10, 27] SOCS molecules have been shown to 
regulate Th2 cytokine signalling both in vitro and in in vivo mouse models of allergic airway 
inflammation, however, it is unclear if similar regulatory mechanisms exist in human asthma. 
In this study we investigated, for the first time, the expression of SOCS1, SOCS2 and SOCS3 
in the airways of healthy controls, mild/moderate asthmatics and severe asthmatics. We show 
that patients with severe asthma and persistent eosinophilic airway inflammation have 
decreased epithelial SOCS1 expression compared to patients with milder more stable asthma.  
This reduced SOCS1 was inversely associated with an IL-13-dependent Th2 gene signature 
and tissue eosinophilia, which appears paradoxical, as one would anticipate IL-13 signalling 
to be associated with increased SOCS1 expression in an attempt to ‘switch off’ IL-13 driven 
responses. It is worth commenting that baseline SOCS1 expression in healthy subjects is low 
(and not different from severe asthmatics), presumably reflecting the absence of pro-
inflammatory cytokine stimuli and thus no requirement for the negative feedback regulator. 
The key difference is that in the severe asthma population with persistent Th2 signalling and 
eosinophilia, the failure of SOCS1 up-regulation is inappropriate. 
This effect appears specific for SOCS1, as we identified no differences in SOCS2 or SOCS3 
expression in relation to disease severity, Th2 signature, or eosinophilic inflammatory 
infiltrate. SOCS2 and SOCS3 have been implicated in animal models of asthma and SOCS 
molecules can interact with each other. For example, SOCS2 has been shown to regulate the 
expression of SOCS1 and SOCS3 via direct interactions [17] and SOCS2 knockout mice 
were shown to have elevated levels of SOCS1 and SOCS3 in T cells.[18] However, our data 
	examining the expression of SOCS molecules in human asthma suggests a specific 
dysregulation of SOCS1 in severe asthma with persistent Th2 inflammation despite high dose 
inhaled corticosteroids. One limiting factor of our study is the cross sectional design, 
therefore we cannot comment on the dynamic changes in SOCS expression. However, the 
pattern of specific SOCS1 down-regulation was consistent across severe asthma patients with 
persistent eosinophilia thus suggesting that it is unlikely to be a transient feature.  
We utilised immunohistochemistry to examine localisation of SOCS proteins and better 
inform our subsequent in vitro mechanistic analysis. SOCS1 was found to be localised 
predominantly to the bronchial epithelium of the airway tissue. This is consistent with 
previous data, whereby mice challenged intra-tracheally with IL-13 displayed SOCS1 
induction localised to the airway epithelium.[15] 
In vitro studies and in vivo animal models have shown SOCS1 attenuates Th2 inflammation. 
Local airway induction of SOCS1 in response to IL-13 administration in an in vivo mouse 
model was associated with suppression of eotaxin levels.[15] In another study, an OVA-
induced airway inflammation model was utilised and SOCS1-/- IFN-γ-/- mice had increased 
eosinophilic infiltration in the lungs and elevated Th2 cytokines compared to IFN-γ-/- control 
mice.[14] These animal studies support our data in human asthma whereby reduced SOCS1 
expression in severe asthma is also associated with  airway eosinophilia and an IL-13-
dependent Th2 gene signature, suggesting epithelial SOCS1 has a central role in regulating 
IL-13 signalling in the airway and airway eosinophilia. Indeed high SOCS1 expression in 
airway eosinophils has been reported to inhibit their response to the IL-5 family 
cytokines.[28]  Therefore SOCS1 deficiency in eosinophils in the airway of severe asthma 
patients may cause increased sensitivity to IL-5 cytokine signaling leading to enhanced 
eosinophil survival and pathologies in the airway.		
	IL-13 is a Th2 cytokine that has been implicated in human asthma and is elevated in severe 
asthma subjects with persistent eosinophilia.[10, 29] IL-13 signals via the STAT6 pathway 
and the absolute requirement of SOCS1 in attenuating Th2 inflammation via inhibition of 
STAT6 phosphorylation has been observed in SOCS1 deficient mouse embryonic 
fibroblasts.[15, 30]  As SOCS1 was localised to the bronchial epithelium of bronchial 
biopsies, we wished to examine the role of SOCS1 in regulating IL-13 epithelial signalling in 
vitro using the bronchial epithelial BEAS-2B cell line and primary bronchial epithelial cells 
(PBECs). CCL26 (eotaxin-3) expression was examined as a downstream readout of IL-13 
signalling as previous studies have found it to be one of the most highly upregulated genes in 
the airways of asthma patients with Th2 inflammation, it is IL-13 dependent and a potent 
eosinophil chemoattractant.[31, 25, 32] Cells stimulated with IL-13 showed SOCS1 mRNA 
was rapidly induced but this was not the case for SOCS2 or SOCS3. This selective induction 
of SOCS1 further supports its role in inhibiting IL-13 driven Th2 inflammation and is 
consistent with our patient data showing no relationship between SOCS2 or SOCS3 
expression and the IL-13 dependent gene signature or airway eosinophilia. As anticipated, 
and consistent with other systems, CCL26 mRNA was induced in BEAS-2B cells and PBECs 
in response to IL-13. Consistent with role of SOCS1 regulating IL-13 signalling, when 
SOCS1 was over-expressed in BEAS-2B and PBEC cultures, IL-13 induction of CCL26 was 
inhibited. We have previously reported in this same cohort of severe asthmatics, that patients 
with an elevated IL-13 dependent-Th2 gene signature, have increased numbers of IL-13+ cells 
infiltrating the epithelium.[10] Taken together, these patients with severe asthma, despite 
being on high dose inhaled corticosteroid treatment, have persistent airway eosinophilia, 
increased intra-epithelial IL-13+ cells, persistent IL-13 signalling in the airway (Th2 gene 
signature) and decreased SOCS1 expression. This suggests a breakdown in regulation of IL-
13 by SOCS1 in these patients and it will be of interest to assess whether SOCS1 expression 
	is modified upon IL-13 inhibition, for example, after treatment with IL-13 antagonists such as 
those currently in phase 2/3 clinical trials.[28, 33, 34]  
A study assessing functional variants of SOCS1 within a population of adult Japanese asthma 
patients found a significant association between the SOCS1 promoter polymorphism, -
1478CA< del, and adult asthma. It is suggested this promoter polymorphism leads to 
increased SOCS1 and inhibition of interferons (IFNs) leading to higher susceptibility to 
virus-induced asthma exacerbations.[35] Another study has recently shown that increased 
nuclear SOCS1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate 
IFNs.[36] However, our data in severe asthmatics would suggest that reduced SOCS1 in the 
epithelium is associated with persistent eosinophilia, which is a major risk factor for 
exacerbations in this population.[37] 
In summary, we have investigated the expression of SOCS1, SOCS2 and SOCS3 within the 
airways of healthy controls, mild/moderate asthmatics, and severe asthmatics. We found that 
SOCS1 was significantly decreased in the airways of severe asthma patients when compared 
to mild/moderate asthma patients. Subjects with persistent eosinophilia and increased Th2 
inflammation within the airway have decreased epithelial SOCS1 expression. In vitro 
investigation of BEAS-2B and primary bronchial epithelial cell cultures showed that SOCS1 
was induced in response to IL-13 stimulation and SOCS1 overexpression led to reduced 
CCL26 mRNA induction in response to IL-13 stimulation. Further work will focus on why 
there is an inappropriate failure to upregulate SOCS1 in the epithelium of patients with severe 
asthma despite persistent Th2 signalling in the airway.  
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	Figure legends 
Figure 1. Increased Th2 inflammatory measures in study participants with asthma. A, 
Peripheral blood eosinophils and B, blood IgE levels increased with increasing asthma 
severity. C, and D, showed a trend of increasing eosinophil numbers in the lamina propria 
and increasing Th2 signature values with increasing asthma severity. E, Eosinophil numbers 
in the lamina propria positively correlated with Th2 biopsy signature (n=40). Black circles 
represent mild/moderate asthma patients and white circles represent severe asthma patients. 
Kruskal-Wallis and Spearman’s Rank tests were employed for statistical analysis. Graphs 
show median and IQR. ** P<0.01, *** P<0.001. 
 
Figure 2. Decreased SOCS1 mRNA expression in bronchial biopsies from severe 
asthmatics compared to mild/moderate asthmatics. A, SOCS1, B, SOCS2 and C, SOCS3 
mRNA expression was analysed in biopsy homogenates from healthy controls (n=17), 
mild/moderate asthmatics (n=29) and severe asthmatics (n=18) using qPCR. Values represent 
–ΔΔCt. Kruskal-Wallis test was employed for statistical analysis. Graphs show median and 
IQR. * P<0.05.  
 
Figure 3. SOCS1 gene expression is decreased in patients with persistent Th2 
inflammation and eosinophilia in the airways. A, SOCS1 and the Th2 biopsy signature 
(n=47) and B, SOCS1 and eosinophil numbers in the lamina propria (n=40) showed a 
significant negative correlation. C, SOCS1 expression was decreased in subjects with high 
airway eosinophilia (≥9.2 eosinophils/mm2 lamina propria, n=26) compared to those with low 
airway eosinophilia (<9.2 eosinophils/mm2 lamina propria, n=26). D, SOCS1 and CCL26 
expression in the airway showed a significant negative correlation (n=44). Black circles 
represent mild/moderate asthma patients and white circles represent severe asthma patients. 
	Mann–Whitney U test and Spearman’s Rank tests were employed for statistical analysis. 
Graphs show median and IQR. *P<0.05, ** P<0.01, *** P<0.001. 
 
Figure 4. Localisation of SOCS1 protein predominantly to the bronchial epithelium.    
A, shows negative control for SOCS1 staining. GMA embedded bronchial biopsy sections 
from B, healthy controls, C, mild/moderate asthmatics and D, severe asthmatics were stained 
for SOCS1 using immunohistochemistry. Staining showed localisation of SOCS1 to the 
bronchial epithelium as depicted by the brown staining. Representative images show negative 
control staining and epithelial SOCS1 biopsy staining (x200 and x400 respectively).  
 
Figure 5. SOCS1 overexpression in BEAS-2B cultures inhibited IL-13 induced CCL26 
mRNA. A, Cells stimulated with IL-13 (50 ng/ml) over 24 hours showed upregulation of 
SOCS1 mRNA but not SOCS2 or SOCS3 mRNA (n=3). B, Cells stimulated with IL-13 (50 
ng/ml) over 24 hours showed upregulation of SOCS1 protein but not SOCS2 or SOCS3 
protein. C, Cells stimulated with IL-13 (50 ng/ml) over 24 hours showed upregulation of 
CCL26 mRNA. D, Cells were transfected with an empty vector or SOCS1 overexpression 
plasmid then probed for SOCS1 and the plasmid Myc-tag to confirm SOCS1 overexpression. 
Cells were then treated with an empty vector or SOCS1 overexpression plasmid for 24 hours, 
stimulated with IL-13 for a further 24 hours then CCL26 mRNA was measured using qPCR. 
Graphs show median and IQR. Mann–Whitney U test employed for statistical analysis (n=4). 
*P<0.05. 
 
Figure 6. SOCS1 overexpression in PBEC cultures inhibited IL-13 induced CCL26 
mRNA. A, Cells stimulated with IL-13 (50 ng/ml) over 24 hours showed upregulation of 
SOCS1 mRNA but not SOCS2 or SOCS3 mRNA (n=5). B, Cells stimulated with IL-13 (50 
	ng/ml) over 24 hours showed upregulation of CCL26 mRNA. C, Cells were transfected with 
an empty vector or SOCS1 overexpression plasmid for 24 hours and stimulated with IL-13 
for a further 24 hours then CCL26 mRNA was measured using qPCR. Graphs show median 
and IQR. Kruskal-Wallis and Students t-test were employed for statistical analysis (n=3). 
*P<0.05, ** P<0.01. 
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Online methods 
Patient cohort 
This study was approved by the Research Ethics Committee of both institutions (Belfast - 
Office of Research and Ethics Committee of Northern Ireland reference 06/NIR02/114 and 
09/NIR02/51 and Leicester - Leicestershire, Northamptonshire, & Rutland Research Ethics 
Committee reference 04/Q2502/74). Mild to moderate asthma patients and healthy volunteers 
were recruited from hospital clinic or by advertisement. 
 
Bronchoscopy  
All participants were current non-smokers with no upper or lower respiratory tract infection 
in the 6 weeks prior to bronchoscopy and were clinically stable and receiving their usual 
medication at the time of bronchoscopy. 
 
Th2 Biopsy Signature  
The Th2 score was calculated by using a generalized procedure. [25] Thirty-eight signature 
genes were selected based on array features corresponding to Th2 signature genes with 
Entrez gene annotation that were previously observed to be upregulated in Th2-high subjects. 
If individual Entrez genes mapped to multiple probes, the probe with the greatest interquartile 
range was retained, and any others were removed. Gene expression values were mean 
centered. Missing Th2 signature gene set values (5/2622 [0.19%]) were substituted by using 
mean replacement. Principal component analysis was conducted on these expression values, 
and PC1 (which retained 39.5% of the variance of the signature gene set) was used as the Th2 
score. 
 
 
Gene expression analyses 
TaqMan® Gene Expression Assays (Applied Biosystems, USA) were purchased and used as 
per manufacturer’s instructions for SOCS1 (Hs00864158_g1), SOCS2 (Hs00919620_m1), 
SOCS3 (Hs02330328_s1), CCL26 (Hs00171146_m1). GAPDH (4333764F) was utilized as a 
housekeeping gene. Universal Human Reference cDNA (#639654, Clontech, CA) was 
utilized as a calibrator sample for bronchial biopsy analysis and untreated cells were used as 
the calibrator for in vitro studies. 
 
Immunohistochemistry (IHC) 
The following primary antibodies were used: mouse monoclonal anti–mast cell tryptase clone 
AA1 (1:1000 dilution; Dako, UK), mouse monoclonal anti–eosinophil major basic protein 
clone BMK-13 (0.4 µg/mL; Monosan, The Netherlands), mouse monoclonal anti-neutrophil 
elastase clone NP57 (1:1000 dilution; Dako, UK), rabbit polyclonal anti-SOCS1 (1 µg/mL; 
Zymed Laboratories, Invitrogen, UK), rabbit polyclonal anti-SOCS2 (1:100 dilution; Cell 
Signaling Technologies, USA), mouse monoclonal anti-SOCS3 clone 1B2 (40 µg/mL; 
Millipore, USA) and appropriate isotype controls (Dako, UK). The following secondary 
antibodies were used: polyclonal rabbit anti-mouse (1:300 dilution) and polyclonal swine 
anti-rabbit (1:300 dilution), both biotinylated antibodies were purchased from Dako, 
Denmark. 
 
Western blotting  
The following primary antibodies were used: rabbit polyclonal anti-SOCS1 (1:1000 dilution, 
Cell Signalling Technology, USA), rabbit polyclonal anti-SOCS2 (1:1000 dilution, Cell 
Signalling Technology, USA), rabbit polyclonal anti-SOCS3 (1:1000 dilution, Cell 
Signalling Technology, USA), anti-c-Myc (9E10) antibody (1:1000 dilution, Santa Cruz 
Biotechnology, USA) and anti-γ-tubulin (1:5000 dilution, Sigma-Aldrich, UK) according to 
manufacturer’s instruction.  
The following secondary antibodies were used: Goat anti-rabbit HRP and goat anti-mouse 
HRP utilised at a 1:10,000 dilution (Bio-Rad, UK). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table E1. Treatment and exacerbation records of asthma patients. 
 
Disease ICS.dose. BDP.equiv. 
OCS.mg. 
prednisone.d.equiv. 
Severe exacerbations 
requiring rescue steroids 
in past year 
Additional controller treatment 
MMA 0 0 0  
MMA 0 0 0  
MMA 0 0 0  
MMA 0 0 0  
MMA 0 0 0  
MMA 0 0 0  
MMA 0 0 0  
MMA 1000 0 1  
MMA 0 0 0  
MMA 0 0 0  
MMA 400 0 0  
MMA 500 0 0 Salmeterol   
MMA 800 0 2 Eformoterol 
MMA 500 0 0  
MMA 100 0 0 Eformoterol 
MMA 800 0 0 Eformoterol bd 
MMA 400 0 0  
MMA 1000 0 0 Salmeterol 
MMA 400 0 0  
MMA 800 0 2 Eformoterol, Theophylline 
MMA 400 0 0 Eformoterol 
MMA 500 0 0  
MMA 200 0 0 Salmeterol 
MMA 400 0 0 Salmeterol  
MMA 400 0 3 Salmeterol  
MMA 400 0 0 Salmeterol 
MMA 800 0 0 Eformoterol, Monteleukast Theophylline 
MMA 800 0 0 Eformoterol, Monteleukast 
MMA 800 0 3 Eformoterol 
SA 1600 0 1 Eformoterol  
SA 1600 10 10 Eformoterol, Monteleukast Theophylline 
SA 800 Kenalog 80 mg monthly 12 Eformoterol, Monteleukast Theophylline 
SA 2000 0 3 Salmeterol  
SA 2000 0 0 salmeterol 
SA 1600 7.5 1 Eformoterol, Monteleukast Ipratropium 
SA 2400 0 4 Eformoterol 
SA 1600 20 12 Eformoterol, Theophylline  
SA 2400 4 12 Eformoterol,  
SA 800 5 0 Eformoterol, Monteleukast Theophylline, Ipratropium 
SA 1200 5 0 Eformoterol, Theophylline 
SA 400 5 2 Eformoterol, Theophylline 
SA 800 10 2 Eformoterol 
SA 2000 10 4 Salmeterol, Monteleukast Theophylline 
SA 2000 20 6 Salmeterol, Theophylline 
SA 1600 0 3 Eformoterol, Theophylline 
SA 1600 10 2 Eformoterol 
SA 1600 0 5 Eformoterol 
 
Mild moderate asthma patient (MMA), severe asthma patient (SA), Beclomethasone 
Dipropionate (BDP). 
 
 
 
 
Table E2. Quantification of mast cells and neutrophils in the lamina propria of bronchial 
biopsy tissue.  
 
Cell type Healthy  
controls 
Mild/Moderate 
asthmatics 
Severe 
asthmatics 
P value 
Mast cell 13.13 
(6.97 – 18.78) 
10.71 
(5.10 – 19.63) 
7.35 
(4.27 – 15.57) 
ns 
Neutrophil 8.43 
(1.58 – 19.68) 
3.24 
(1.08 – 12.06) 
6.33 
(0.16 – 14.50) 
ns 
 
IHC was carried out to identify mast cell and neutrophil numbers in bronchial biopsies 
obtained from healthy controls, mild/moderate and severe asthmatics. The area of lamina 
propria was measured in each biopsy, positively stained cells were counted and expressed as 
the number of positive cells/mm2 of tissue. Kruskal-Wallis tests were employed for statistical 
analysis. Table shows median and IQR. ns = not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Online figure legends  
Figure E1. Identification of eosinophils, mast cells and neutrophils in bronchial biopsies. 
Bronchial biopsies were embedded in glycol methacrylate (GMA), sectioned and stained 
using IHC. A, Representative mouse IGg1 isotype control staining. Antibodies targeting B, 
eosinophilic major basic protein, C, mast cell tryptase and D, neutrophil elastase were utilised 
for the identification of each cell type. Representative images show biopsy staining captured 
at x200 and inserts show biopsy image captured at x400. 
 
Figure E2. Mast cells and neutrophils in the lamina propria do not correlate with biopsy 
Th2 signature. A, The number of mast cells in the lamina propria and B, the number of 
neutrophils in the lamina propria of bronchial biopsies do not correlate with the biopsy Th2 
signature. Spearman’s Rank test was employed for statistical analysis. ns = not significant. 
 
Figure E3. Significantly reduced SOCS1 mRNA expression observed in bronchial 
biopsies from severe asthmatics receiving high dose steroid treatment. A, SOCS1, B, 
SOCS2 and C, SOCS3 mRNA levels in bronchial biopsies were measured in healthy controls (n=17), 
asthmatics receiving no steroid (n=9), asthmatics receiving low dose steroid treatment of <1000 
µg/day of BDP equivalent (n=19) and asthmatics receiving high dose steroid treatment of >1000 
µg/day of BDP equivalent (n=18). Data is expressed as median and inter-quartile range and a Kruskal-
Wallis test with Dunn’s multiple comparison test was employed for statistical analysis. * P<0.05. 
 
Figure E4. SOCS2 and SOCS3 bronchial biopsy expression do not correlate with biopsy 
Th2 signature or eosinophil numbers. A, SOCS2 and SOCS3 biopsy expression do not 
correlate with Th2 biopsy signature and B, SOCS2 and SOCS3 biopsy expression do not 
correlate with eosinophil numbers in the lamina propria. Spearman’s Rank test was employed 
for statistical analysis. ns = not significant. 
 
Figure E5. SOCS2 and SOCS3 bronchial biopsy expression are not different between 
patients with high and low biopsy eosinophil numbers. There was no difference observed 
in A, SOCS2 and B, SOCS3 expression in subjects with high airway eosinophilia (≥9.2 
eosinophils/mm2 lamina propria, n=26) compared to those with low airway eosinophilia (<9.2 
eosinophils/mm2 lamina propria, n=26). Mann–Whitney U test was employed for statistical 
analysis. Graphs show median and IQR.  
 
Figure E6. Localisation of SOCS2 and SOCS3 protein in bronchial biopsies. Sections 
were cut from GMA embedded bronchial biopsies of healthy controls, mild/moderate 
asthmatics and severe asthmatics. Sections were stained for SOCS2 and SOCS3 using 
immunohistochemistry. Representative images shown (x400). 
 
Figure E7.	 Measuring transfection efficiency in PBEC cultures. a) PBECs were 
transfected by electroporation (2 pulses, 1400 V, 20 ms) for mock transfection or with GFP 
tagged plasmid to measure transfection efficiency. Cells were harvested for FACS analysis 
18 hours post transfection. Mock transfected cells were utilized as the experimental control. 
 
 
 
 
 
 
 
 
 
